The 18-week PFS rate in the pemetrexed , sunitinib , and combination arms was 54 % ( 95 % confidence interval [ CI ] , 40-71 ) , 37 % ( 95 % CI , 25-54 ) , and 48 % ( 95 % CI , 35-66 ) , respectively ( p = 0.25 ) .